

In the Specification:

Please replace the paragraph beginning at page 7, line 15 with the following rewritten paragraph:

C<sub>1</sub> -- Figs. 8A-E depict the double stranded nucleotide sequence (SEQ ID NO:99) for phage-display antibody vector phMB4-19-1.6 in Example 3 and the amino acid sequences encoded thereby (SEQ ID NO's 100, 130 and 131).--

In the Claims:

Please cancel claim 48.

Please amend claims 47, 49-52 as follows:

C<sub>2</sub> 47. (Amended) The method of claim 43, said humanized anti-VEGF antibody having a heavy chain and a light chain, wherein the heavy chain comprises a variable domain comprising the following complementarity determining region (CDR) amino acid sequences: CDRH1 (GYX<sub>1</sub>FTX<sub>2</sub>YGMN, wherein X<sub>1</sub> is T or D and X<sub>2</sub> is N or H; SEQ ID NO: 128), CDRH2 (WINTYTGEPTYAADFQR; SEQ ID NO:2) and CDRH3 (YPX<sub>1</sub>YYGX<sub>2</sub>SHWYFDV, wherein X<sub>1</sub> is Y or H and X<sub>2</sub> is S or T; SEQ ID NO: 129).

49. (Amended) The method of claim 47, wherein the heavy chain comprises a variable domain comprising the following CDR amino acid sequences: CDRH 1 (GYTFTNYGMN; SEQ ID NO: 1), CDRH2 (WINTYTGEPTYAADFQR; SEQ ID NO:2) and CDRH3 (YPHYYGSSHWYFDV; SEQ ID NO:3).

C<sub>3</sub> 50. (Amended) The method of claim 47, wherein the light chain of the humanized anti-VEGF antibody comprises a variable domain comprising the following CDR amino acid sequences: CDRL1 (SASQDISNYLN; SEQ ID NO:4), CDRL2 (FTSSLHS SEQ ID NO:5) and CDRL3 (QQYSTVPWT; SEQ ID NO:6).

51. (Amended) The method of claim 43, said humanized anti-VEGF antibody comprising a heavy chain variable domain sequence of SEQ ID NO:115 and a light chain variable domain sequence of SEQ ID NO:116.

✓

✓